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Abstract 
Gene editing is the introduction of directed modifications in the genome, a process boosted to 
therapeutic levels by the use of designer nucleases. Building on the experience of ex vivo 
gene therapy for severe combined immunodeficiencies, it is likely that gene editing of 
haematopoietic stem/progenitor cells (HSPC) for correction of inherited blood diseases will 
be an early clinical application. Here we show molecular evidence of gene correction in a 
mouse model of primary immunodeficiency. In vitro experiments in Prkdc scid fibroblasts 
using designed zinc finger nucleases (ZFN) and a repair template demonstrated molecular 
and functional correction of the defect. Following transplantation of ex vivo gene-edited 
Prkdc scid HSPC, definite proof of the ability of these cells to mediate some level of 
reconstitution has been obtained by deep sequencing of tissues from some of the recipients, 
which carried the expected genomic signature of ZFN-driven gene correction (correction of 
the scid mutation associated to the introduction of a BsaWI diagnostic site). This signature 
has been observed in peripheral blood mononuclear cells (PBMC), thymus, spleen and 
purified spleen CD3 and CD8 T-cells. Levels are variable in the positive primary transplanted 
animals, higher with integration-proficient lentiviral vector (IPLV)-ZFN than integration-
deficient lentiviral vector (IDLV)-ZFN, and were also observed in secondary recipients. In 
some primary and secondary transplant recipients we also detected double-positive CD4/CD8 
T-cells in thymus and single-positive T-cells in blood, but no other evidence of immune 
reconstitution. We consider the presence of the genome editing signature proof that 
reconstitution can be achieved, albeit inefficiently both in terms of the number of positive 
animals and the levels in different tissues. This Prkdc model is deficient in non-homologous 
end-joining, and this deficiency may be responsible for the frequency of a recurrent 44-bp 
deletion including the ZFN target site that we have observed in multiple samples in vitro and 
ex vivo. This highlights the importance of considering the possible effect of DNA damage 
repair defects on gene editing strategies. 
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